Shansheng Pharmaceutical (02096) announced that the Group has entered into a cooperation agreement with Maibo Pharmaceutical (02181) for CMAB009, under which the Group will acquire the exclusive commercial interest of CMAB009 in mainland China (the cooperation area) (including, but not limited to, the right to sales management, marketing, formulation and adjustment of related strategies and related benefits of CMAB009). On the basis of complying with the provisions of this agreement, the Group will have the right to provide exclusive promotion services related to CMAB009 in the cooperation area.
CMAB009 is a recombinant anti-epidermal growth factor receptor (EGFR) chimeric monoclonal antibody combined with FOLFIRI for first-line treatment of metastatic colorectal cancer (mCRC).